US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Park Hotels & Resorts Inc.

15.53

+0.11000.71%

Post-market: 15.530.00000.00%19:30 EDT

Volume:3.29M

Turnover:51.08M

Market Cap:3.13B

PE:-18.79

High:15.62

Open:15.62

Low:15.39

Close:15.42

52wk High:16.20

52wk Low:9.84

Shares:201.40M

Float Shares:195.63M

Volume Ratio:0.94

T/O Rate:1.68%

Dividend:1

Dividend Rate:6.44%

EPS(TTM):-0.8265

EPS(LYR):-1.4300

ROE:-4.86%

ROA:2.75%

PB:1.01

PE(LYR):-10.86

Loading ...

Overview Company News Filings

Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

Press Release: Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update

Galmed reports results from first-in-man PK study of Aramchol Meglumine

Press Release: Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Park Hotels & Resorts Price Target Maintained With a $12.00/Share by Cantor Fitzgerald

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Park Hotels & Resorts Is Maintained at Equal-Weight by Morgan Stanley

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Press Release: Sionna Therapeutics Reports First Quarter 2026 Financial Results

Erasca Reports First Quarter 2026 Business Updates and Financial Results

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing

Press Release: Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

Live Broadcast Preview: Guangdong BA League - Meizhou vs. Qingyuan! Tonight, Witness the "Qing-Mei" Rivalry Face-Off

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Press Release: Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/PK/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PK","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PK\",,,,,undefined,":{"symbol":"PK","market":"US","secType":"STK","nameCN":"Park Hotels & Resorts Inc.","latestPrice":15.53,"timestamp":1790971200000,"preClose":15.42,"halted":0,"volume":3291474,"hourTrading":{"tag":"盘后","latestPrice":15.53,"preClose":15.53,"latestTime":"19:30 EDT","volume":119410,"amount":1853147.4932,"timestamp":1790983804660,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0071335927367055406,"floatShares":195633448,"shares":201398439,"eps":-0.826466,"marketStatus":"Market Closed","change":0.11,"latestTime":"10-02 16:00:00 EDT","open":15.62,"high":15.62,"low":15.385,"amount":51079173.743568,"amplitude":0.01524,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.826466,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":15.42,"dividendRate":0.064392,"preHourTrading":{"tag":"盘前","latestPrice":15.42,"preClose":15.42,"latestTime":"09:14 EDT","volume":204,"amount":3191.62284,"timestamp":1790946867761,"change":0,"changeRate":0,"amplitude":0.027419},"postHourTrading":{"tag":"盘后","latestPrice":15.53,"preClose":15.53,"latestTime":"19:30 EDT","volume":119410,"amount":1853147.4932,"timestamp":1790983804660,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9390609532822697,"impliedVol":0.3248,"impliedVolPercentile":0.1633},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PK\",,,,,undefined,":{"symbol":"PK","floatShares":195633448,"roa":"2.75%","roe":"-4.86%","lyrEps":-1.43,"volumeRatio":0.9390609532822697,"shares":201398439,"dividePrice":1,"high":15.62,"amplitude":0.01524,"preClose":15.42,"low":15.385,"week52Low":9.84,"pbRate":"1.01","psRate":"1.23","week52High":16.2,"institutionHeld":0,"latestPrice":15.53,"eps":-0.826466,"divideRate":0.064392,"volume":3291474,"delay":0,"ttmEps":-0.826466,"open":15.62,"prevYearClose":10.46,"prevWeekClose":15.43,"prevMonthClose":15.42,"prevQuarterClose":15.42,"fiveDayClose":15.43,"twentyDayClose":15.08,"sixtyDayClose":14.14,"dividendPayoutRate":1.373460620431404,"dividendFrequency":"Q","dividendGrowthYears":0,"dividendGrowthRate":-0.28571428571428564,"fiveYearAvgDividendRate":0.07559574201047665},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PK\",params:#limit:5,,,undefined,":[{"date":"2026-11-04","symbol":"PK","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2026/09","expectedEps":0.34,"defaultRemindTime":1793826000000,"name":null,"time":"Post-Mkt","dateTimestamp":1793768400000,"actualEps":null},{"date":"2026-09-30","symbol":"PK","amount":0.25,"announcedDate":"2026-07-31","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-30","defaultRemindTime":1790775000000,"name":"Park Hotels & Resorts Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-15","payableDate":"2026-09-30","currency":"USD","dateTimestamp":1790740800000,"payDate":"2026-10-15"},{"market":"US","date":"2026-08-06","symbol":"PK","fiscalQuarterEnding":"2026/06","expectedEps":0.57,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":0.7},{"date":"2026-06-30","symbol":"PK","amount":0.25,"announcedDate":"2026-04-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-30","defaultRemindTime":1782826200000,"name":"Park Hotels & Resorts Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-15","payableDate":"2026-06-30","currency":"USD","dateTimestamp":1782792000000,"payDate":"2026-07-15"},{"market":"US","date":"2026-04-30","symbol":"PK","fiscalQuarterEnding":"2026/03","expectedEps":0.38,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1777521600000,"reportTimeType":"post","actualEps":0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PK\",market:\"US\",,,undefined,":[{"executeDate":"2017-03-29","recordDate":"2017-03-31","paymentDate":"2017-04-17","value":0.43,"currency":"USD"},{"executeDate":"2017-06-28","recordDate":"2017-06-30","paymentDate":"2017-07-17","value":0.43,"currency":"USD"},{"executeDate":"2017-09-28","recordDate":"2017-09-29","paymentDate":"2017-10-16","value":0.43,"currency":"USD"},{"executeDate":"2017-12-28","recordDate":"2017-12-29","paymentDate":"2018-01-16","value":0.55,"currency":"USD"},{"executeDate":"2018-03-28","recordDate":"2018-03-30","paymentDate":"2018-04-16","value":0.43,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PK\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1765,"buy":0.1176,"hold":0.5882,"sell":0.1176,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.5882,"analysts":17,"updateTime":1790654400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PK\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PK","date":"2026-10-02","current":-18.790852,"percent":0.226524,"low":-196.066894,"twenty":-46.400028,"median":-5.721411,"eighty":17.858097,"high":55.399897,"avg":-11.664519,"sd":52.712086,"marketCap":3104637048},"quantilePoints":[{"date":"2021-10-08","current":-5.721411,"twenty":-3.607845,"median":12.595518,"eighty":24.655885,"marketCap":4571407660},{"date":"2021-10-15","current":-5.659254,"twenty":-3.625758,"median":12.578404,"eighty":24.655885,"marketCap":4521744152},{"date":"2021-10-22","current":-5.505341,"twenty":-3.649856,"median":12.569511,"eighty":24.645785,"marketCap":4398767847},{"date":"2021-10-29","current":-5.484622,"twenty":-3.670075,"median":12.545167,"eighty":24.625583,"marketCap":4382213344},{"date":"2021-11-05","current":-8.201051,"twenty":-3.681985,"median":12.518997,"eighty":24.605382,"marketCap":4994440260},{"date":"2021-11-12","current":-7.56811,"twenty":-3.701263,"median":12.505104,"eighty":24.575079,"marketCap":4608979198},{"date":"2021-11-19","current":-7.339009,"twenty":-3.720957,"median":12.481428,"eighty":24.44377,"marketCap":4469456483},{"date":"2021-11-26","current":-6.989532,"twenty":-3.729965,"median":12.465978,"eighty":24.427609,"marketCap":4256625222},{"date":"2021-12-03","current":-6.488616,"twenty":-3.750955,"median":12.411262,"eighty":24.415488,"marketCap":3951567081},{"date":"2021-12-10","current":-7.129323,"twenty":-3.770233,"median":12.390156,"eighty":24.397368,"marketCap":4341757726},{"date":"2021-12-17","current":-6.752665,"twenty":-3.792938,"median":12.369502,"eighty":24.247831,"marketCap":4112372922},{"date":"2021-12-23","current":-7.490449,"twenty":-3.83227,"median":12.348324,"eighty":24.162969,"marketCap":4561683362},{"date":"2021-12-31","current":-7.331243,"twenty":-3.873903,"median":12.336915,"eighty":24.124587,"marketCap":4464726899},{"date":"2022-01-07","current":-7.692369,"twenty":-3.888468,"median":12.314228,"eighty":24.072063,"marketCap":4684652535},{"date":"2022-01-14","current":-7.548695,"twenty":-3.917478,"median":12.283673,"eighty":24.03368,"marketCap":4597155239},{"date":"2022-01-21","current":-7.032246,"twenty":-3.996222,"median":12.241172,"eighty":24.02964,"marketCap":4282637931},{"date":"2022-01-28","current":-6.803145,"twenty":-4.087905,"median":12.214275,"eighty":24.013479,"marketCap":4143115216},{"date":"2022-02-04","current":-7.051662,"twenty":-4.210886,"median":12.177189,"eighty":23.964995,"marketCap":4294461890},{"date":"2022-02-11","current":-7.339009,"twenty":-4.305038,"median":12.115818,"eighty":23.924593,"marketCap":4469456483},{"date":"2022-02-18","current":-9.97933,"twenty":-4.379327,"median":12.077002,"eighty":23.906411,"marketCap":4580512556},{"date":"2022-02-25","current":-9.762948,"twenty":-4.434604,"median":12.034907,"eighty":23.88419,"marketCap":4481193234},{"date":"2022-03-04","current":-9.294121,"twenty":-4.477502,"median":11.989722,"eighty":23.857928,"marketCap":4266001369},{"date":"2022-03-11","current":-9.515655,"twenty":-4.530065,"median":11.874947,"eighty":23.585208,"marketCap":4367685437},{"date":"2022-03-18","current":-9.793479,"twenty":-4.62021,"median":11.802039,"eighty":23.304408,"marketCap":4495206674},{"date":"2022-03-25","current":-9.839796,"twenty":-4.668569,"median":11.613959,"eighty":23.136735,"marketCap":4516466191},{"date":"2022-04-01","current":-10.045649,"twenty":-4.723283,"median":11.244693,"eighty":22.801391,"marketCap":4610952931},{"date":"2022-04-08","current":-8.795089,"twenty":-4.748358,"median":11.177001,"eighty":22.577155,"marketCap":4036945983},{"date":"2022-04-14","current":-9.860381,"twenty":-4.774334,"median":11.132722,"eighty":22.280194,"marketCap":4525914865},{"date":"2022-04-22","current":-9.999332,"twenty":-4.831692,"median":11.002063,"eighty":21.938028,"marketCap":4589693414},{"date":"2022-04-29","current":-10.143429,"twenty":-4.933265,"median":10.846102,"eighty":20.988446,"marketCap":4655834133},{"date":"2022-05-06","current":-13.808923,"twenty":-5.010567,"median":10.72108,"eighty":20.329014,"marketCap":4501708843},{"date":"2022-05-13","current":-13.178967,"twenty":-5.093895,"median":7.386072,"eighty":20.146479,"marketCap":4296343172},{"date":"2022-05-20","current":-11.861786,"twenty":-5.147058,"median":6.828781,"eighty":19.994366,"marketCap":3866942225},{"date":"2022-05-27","current":-13.143174,"twenty":-5.175677,"median":6.45202,"eighty":19.781409,"marketCap":4284674668},{"date":"2022-06-03","current":-13.207601,"twenty":-5.20439,"median":6.373529,"eighty":19.661408,"marketCap":4305677976},{"date":"2022-06-10","current":-12.055068,"twenty":-5.217352,"median":6.1773,"eighty":18.57907,"marketCap":3929952147},{"date":"2022-06-17","current":-10.229627,"twenty":-5.287145,"median":5.839785,"eighty":18.013987,"marketCap":3334858443},{"date":"2022-06-24","current":-10.1652,"twenty":-5.323251,"median":5.651405,"eighty":17.603643,"marketCap":3313855136},{"date":"2022-07-01","current":-9.70705,"twenty":-5.360954,"median":5.101963,"eighty":17.208917,"marketCap":3164498284},{"date":"2022-07-08","current":-9.85738,"twenty":-5.388567,"median":3.861793,"eighty":17.068349,"marketCap":3213506001},{"date":"2022-07-15","current":-9.921808,"twenty":-5.409668,"median":2.45556,"eighty":16.809931,"marketCap":3234509308},{"date":"2022-07-22","current":-10.487336,"twenty":-5.439477,"median":2.417283,"eighty":16.594109,"marketCap":3418871672},{"date":"2022-07-29","current":-11.160244,"twenty":-5.472783,"median":2.404801,"eighty":15.354106,"marketCap":3638239547},{"date":"2022-08-05","current":-56.398031,"twenty":-5.505341,"median":2.387327,"eighty":15.148576,"marketCap":3383881882},{"date":"2022-08-12","current":-60.145409,"twenty":-5.52902,"median":2.299955,"eighty":15.006602,"marketCap":3608724532},{"date":"2022-08-19","current":-55.873399,"twenty":-5.552107,"median":2.257518,"eighty":14.887345,"marketCap":3352403911},{"date":"2022-08-26","current":-53.287708,"twenty":-5.563474,"median":2.212781,"eighty":14.845845,"marketCap":3197262483},{"date":"2022-09-02","current":-52.238442,"twenty":-5.614856,"median":2.207821,"eighty":14.818112,"marketCap":3134306541},{"date":"2022-09-09","current":-54.786659,"twenty":-5.644455,"median":2.197209,"eighty":14.800268,"marketCap":3287199543},{"date":"2022-09-16","current":-52.051073,"twenty":-5.663398,"median":2.187137,"eighty":14.752289,"marketCap":3123064408},{"date":"2022-09-23","current":-44.593792,"twenty":-5.688853,"median":2.168482,"eighty":14.705619,"marketCap":2675627535},{"date":"2022-09-30","current":-42.195471,"twenty":-5.714833,"median":2.125089,"eighty":14.651669,"marketCap":2531728239},{"date":"2022-10-07","current":-43.582,"twenty":-5.729107,"median":2.082185,"eighty":14.616649,"marketCap":2614920019},{"date":"2022-10-14","current":-44.219054,"twenty":-5.777649,"median":2.070313,"eighty":14.587307,"marketCap":2653143270},{"date":"2022-10-21","current":-47.216957,"twenty":-5.925642,"median":2.05882,"eighty":14.530184,"marketCap":2833017390},{"date":"2022-10-28","current":-48.828329,"twenty":-6.246611,"median":2.029326,"eighty":14.486979,"marketCap":2929699729},{"date":"2022-11-04","current":43.862859,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2675634425},{"date":"2022-11-11","current":47.03278,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2868999602},{"date":"2022-11-18","current":45.005505,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2745335826},{"date":"2022-11-25","current":45.742696,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2790304471},{"date":"2022-12-02","current":46.553606,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2839769982},{"date":"2022-12-09","current":45.41096,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2770068581},{"date":"2022-12-16","current":44.342034,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2704864044},{"date":"2022-12-23","current":42.941371,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2619423617},{"date":"2022-12-30","current":43.457404,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2650901669},{"date":"2023-01-06","current":44.010298,"twenty":-6.452657,"median":2.015912,"eighty":14.499284,"marketCap":2684628154},{"date":"2023-01-13","current":46.332449,"twenty":-6.452657,"median":2.015912,"eighty":14.544715,"marketCap":2826279388},{"date":"2023-01-20","current":47.585674,"twenty":-6.452657,"median":2.015912,"eighty":14.591155,"marketCap":2902726086},{"date":"2023-01-27","current":53.188324,"twenty":-6.452657,"median":2.015912,"eighty":14.629303,"marketCap":3244487794},{"date":"2023-02-03","current":54.478409,"twenty":-6.452657,"median":2.015912,"eighty":14.659241,"marketCap":3323182924},{"date":"2023-02-10","current":52.598572,"twenty":-6.452657,"median":2.015912,"eighty":14.710351,"marketCap":3208512877},{"date":"2023-02-17","current":50.681875,"twenty":-6.452657,"median":2.015912,"eighty":14.776825,"marketCap":3091594398},{"date":"2023-02-24","current":19.081678,"twenty":-6.452657,"median":2.015912,"eighty":14.800268,"marketCap":3091231855},{"date":"2023-03-03","current":19.2873,"twenty":-6.452657,"median":2.020509,"eighty":14.820409,"marketCap":3124542543},{"date":"2023-03-10","current":17.080295,"twenty":-6.452657,"median":2.020509,"eighty":14.858004,"marketCap":2767007824},{"date":"2023-03-17","current":15.80726,"twenty":-6.452657,"median":2.020509,"eighty":14.898703,"marketCap":2560776060},{"date":"2023-03-24","current":15.423721,"twenty":-6.452657,"median":2.034301,"eighty":15.020423,"marketCap":2498642845},{"date":"2023-03-31","current":16.930479,"twenty":-6.449731,"median":2.061884,"eighty":15.148576,"marketCap":2742737617},{"date":"2023-04-06","current":16.355172,"twenty":-6.449731,"median":2.08027,"eighty":15.339767,"marketCap":2649537795},{"date":"2023-04-14","current":16.231891,"twenty":-6.452657,"median":2.187137,"eighty":15.656584,"marketCap":2629566405},{"date":"2023-04-21","current":16.1771,"twenty":-6.452657,"median":2.20399,"eighty":16.160663,"marketCap":2620690231},{"date":"2023-04-28","current":15.916842,"twenty":-6.452657,"median":3.861793,"eighty":16.193538,"marketCap":2578528407},{"date":"2023-05-05","current":10.781494,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2716936387},{"date":"2023-05-12","current":11.431806,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2880815089},{"date":"2023-05-19","current":11.705622,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2949816648},{"date":"2023-05-26","current":11.13232,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2805344634},{"date":"2023-06-02","current":11.115206,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2801032037},{"date":"2023-06-09","current":12.184799,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":3070569377},{"date":"2023-06-16","current":11.243558,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2833376518},{"date":"2023-06-23","current":10.71304,"twenty":-6.455582,"median":4.787996,"eighty":16.201756,"marketCap":2699685997},{"date":"2023-06-30","current":10.926958,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2753593465},{"date":"2023-07-07","current":11.226444,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2829063920},{"date":"2023-07-14","current":11.799746,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2973535934},{"date":"2023-07-21","current":11.260671,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2837689115},{"date":"2023-07-28","current":10.76438,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2712623789},{"date":"2023-08-04","current":-57.485197,"twenty":-6.501042,"median":3.861793,"eighty":16.209975,"marketCap":2759289480},{"date":"2023-08-11","current":-60.090736,"twenty":-6.750335,"median":-2.450979,"eighty":16.209975,"marketCap":2884355344},{"date":"2023-08-18","current":-56.854736,"twenty":-6.930509,"median":-2.566048,"eighty":16.209975,"marketCap":2729027307},{"date":"2023-08-25","current":-56.854736,"twenty":-7.00324,"median":-2.678241,"eighty":16.209975,"marketCap":2729027307},{"date":"2023-08-31","current":-58.203069,"twenty":-7.047778,"median":-2.730022,"eighty":16.209975,"marketCap":2793747322},{"date":"2023-09-08","current":-56.225513,"twenty":-7.135536,"median":-2.76742,"eighty":16.220933,"marketCap":2698824633},{"date":"2023-09-13","current":-59.641292,"twenty":-7.238826,"median":-2.81236,"eighty":16.220933,"marketCap":2862782005},{"date":"2023-09-20","current":-56.49518,"twenty":-7.292412,"median":-2.856599,"eighty":16.226412,"marketCap":2711768636},{"date":"2023-09-29","current":-56.270458,"twenty":-7.33179,"median":-2.859478,"eighty":16.256547,"marketCap":2700981967},{"date":"2023-10-06","current":-54.068179,"twenty":-7.350658,"median":-2.872421,"eighty":16.256547,"marketCap":2595272609},{"date":"2023-10-13","current":-54.023235,"twenty":-7.41434,"median":-2.928517,"eighty":16.256547,"marketCap":2593115275},{"date":"2023-10-20","current":-52.944568,"twenty":-7.474917,"median":-3.004751,"eighty":16.256547,"marketCap":2541339263},{"date":"2023-10-23","current":-52.405235,"twenty":-7.491226,"median":-3.007627,"eighty":16.256547,"marketCap":2515451257},{"date":"2023-11-03","current":-48.333767,"twenty":-7.537046,"median":-3.046463,"eighty":16.355172,"marketCap":2706690937},{"date":"2023-11-10","current":-48.821216,"twenty":-7.614707,"median":-3.102759,"eighty":16.355172,"marketCap":2733988086},{"date":"2023-11-17","current":-52.758411,"twenty":-7.692369,"median":-3.147149,"eighty":16.355172,"marketCap":2954470996},{"date":"2023-11-24","current":-54.558271,"twenty":-8.07291,"median":-3.21274,"eighty":16.355172,"marketCap":3055263184},{"date":"2023-12-01","current":-55.60819,"twenty":-8.887723,"median":-3.353198,"eighty":16.355172,"marketCap":3114058626},{"date":"2023-12-08","current":-56.170646,"twenty":-9.20165,"median":-3.416563,"eighty":16.355172,"marketCap":3145556185},{"date":"2023-12-13","current":-57.820518,"twenty":-9.294121,"median":-3.460856,"eighty":16.355172,"marketCap":3237949024},{"date":"2023-12-22","current":-62.432661,"twenty":-9.507389,"median":-3.497732,"eighty":16.36339,"marketCap":3496229004},{"date":"2024-01-05","current":-59.020425,"twenty":-9.574387,"median":-3.519891,"eighty":16.393525,"marketCap":3305143815},{"date":"2024-01-12","current":-60.445315,"twenty":-9.664756,"median":-3.542049,"eighty":16.393525,"marketCap":3384937630},{"date":"2024-01-19","current":-59.99535,"twenty":-9.712777,"median":-3.553469,"eighty":16.401744,"marketCap":3359739584},{"date":"2024-01-26","current":-58.232986,"twenty":-9.763771,"median":-3.571596,"eighty":16.393525,"marketCap":3261047233},{"date":"2024-02-02","current":-66.888565,"twenty":-9.823019,"median":-3.581378,"eighty":16.393525,"marketCap":3210651139},{"date":"2024-02-09","current":-57.220565,"twenty":-9.869644,"median":-3.59147,"eighty":16.393525,"marketCap":3204351628},{"date":"2024-02-16","current":-57.220565,"twenty":-9.956321,"median":-3.604489,"eighty":16.393525,"marketCap":3204351628},{"date":"2024-02-23","current":-60.89528,"twenty":-10.043591,"median":-3.622011,"eighty":16.393525,"marketCap":3410135677},{"date":"2024-03-01","current":35.936019,"twenty":-10.056469,"median":-3.625758,"eighty":16.447807,"marketCap":3485793844},{"date":"2024-03-08","current":37.18843,"twenty":-10.056469,"median":-3.625758,"eighty":16.567212,"marketCap":3607277745},{"date":"2024-03-15","current":36.961243,"twenty":-10.056469,"median":-3.625758,"eighty":16.670221,"marketCap":3585240545},{"date":"2024-03-22","current":38.523902,"twenty":-10.056469,"median":-3.625758,"eighty":16.766106,"marketCap":3736818537},{"date":"2024-03-28","current":38.306866,"twenty":-10.056469,"median":-3.625758,"eighty":16.809931,"marketCap":3715766038},{"date":"2024-04-05","current":37.156575,"twenty":-10.059306,"median":-3.629041,"eighty":16.978896,"marketCap":3604187794},{"date":"2024-04-12","current":37.894498,"twenty":-10.059306,"median":-3.629041,"eighty":17.16064,"marketCap":3675766290},{"date":"2024-04-19","current":35.007918,"twenty":-10.059306,"median":-3.629041,"eighty":17.258612,"marketCap":3395768056},{"date":"2024-04-26","current":35.44199,"twenty":-10.056469,"median":-3.625758,"eighty":17.840762,"marketCap":3437873054},{"date":"2024-05-03","current":36.498796,"twenty":-10.056469,"median":-3.625758,"eighty":18.170174,"marketCap":3357889189},{"date":"2024-05-10","current":36.511207,"twenty":-10.056469,"median":-3.625758,"eighty":18.755351,"marketCap":3359031034},{"date":"2024-05-17","current":37.541304,"twenty":-10.056469,"median":-3.625758,"eighty":19.13678,"marketCap":3453799934},{"date":"2024-05-24","current":36.396752,"twenty":-10.056469,"median":-3.625758,"eighty":19.228198,"marketCap":3348501156},{"date":"2024-05-31","current":35.595565,"twenty":-10.056469,"median":-3.625758,"eighty":19.551549,"marketCap":3274792011},{"date":"2024-06-07","current":34.863052,"twenty":-10.056469,"median":-3.625758,"eighty":19.788169,"marketCap":3207400793},{"date":"2024-06-14","current":34.496795,"twenty":-10.059306,"median":-3.629041,"eighty":19.972394,"marketCap":3173705183},{"date":"2024-06-21","current":33.832955,"twenty":-10.062143,"median":-3.632324,"eighty":20.117746,"marketCap":3112631892},{"date":"2024-06-28","current":34.061866,"twenty":-10.071657,"median":-3.634664,"eighty":20.170141,"marketCap":3133691648},{"date":"2024-07-05","current":33.398026,"twenty":-10.071657,"median":-3.634664,"eighty":20.359437,"marketCap":3072618356},{"date":"2024-07-12","current":32.779968,"twenty":-10.071657,"median":-3.634664,"eighty":20.997672,"marketCap":3015757016},{"date":"2024-07-15","current":33.466699,"twenty":-10.071657,"median":-3.634664,"eighty":21.055774,"marketCap":3078936283},{"date":"2024-08-02","current":10.070358,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3081529526},{"date":"2024-08-09","current":9.455895,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2893503995},{"date":"2024-08-16","current":9.763127,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2987516760},{"date":"2024-08-23","current":10.179596,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3114956286},{"date":"2024-08-30","current":10.309316,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3154650565},{"date":"2024-09-06","current":9.742645,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2981249243},{"date":"2024-09-13","current":9.408104,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2878879787},{"date":"2024-09-20","current":10.718957,"twenty":-10.150883,"median":-3.673418,"eighty":21.101408,"marketCap":3280000919},{"date":"2024-09-27","current":10.084013,"twenty":-10.150883,"median":-3.673418,"eighty":20.560563,"marketCap":3085707871},{"date":"2024-10-04","current":9.585615,"twenty":-10.150883,"median":-3.673418,"eighty":20.205634,"marketCap":2933198274},{"date":"2024-10-11","current":9.756299,"twenty":-10.150883,"median":-3.673418,"eighty":20.146479,"marketCap":2985427588},{"date":"2024-10-18","current":9.626579,"twenty":-10.150883,"median":-3.673418,"eighty":20.146479,"marketCap":2945733309},{"date":"2024-10-25","current":9.462723,"twenty":-10.150883,"median":-3.673418,"eighty":20.138028,"marketCap":2895593168},{"date":"2024-10-31","current":8.714822,"twenty":-10.150883,"median":-3.673418,"eighty":19.647887,"marketCap":2902035670},{"date":"2024-11-08","current":9.117754,"twenty":-10.153746,"median":-3.674208,"eighty":19.166669,"marketCap":3036211945},{"date":"2024-11-15","current":9.111555,"twenty":-10.153746,"median":-3.674208,"eighty":18.78122,"marketCap":3034147899},{"date":"2024-11-22","current":9.099159,"twenty":-10.153746,"median":-3.674208,"eighty":16.930479,"marketCap":3030019806},{"date":"2024-11-29","current":9.638414,"twenty":-10.153746,"median":-3.674208,"eighty":16.766106,"marketCap":3209591825},{"date":"2024-12-06","current":9.756182,"twenty":-10.153746,"median":-3.674208,"eighty":16.574337,"marketCap":3248808703},{"date":"2024-12-13","current":9.53924,"twenty":-10.153746,"median":-3.674208,"eighty":16.377088,"marketCap":3176567086},{"date":"2024-12-20","current":8.968994,"twenty":-10.153746,"median":-3.674208,"eighty":16.1771,"marketCap":2986674836},{"date":"2024-12-27","current":9.334695,"twenty":-10.153746,"median":-3.674208,"eighty":15.960675,"marketCap":3108453562},{"date":"2025-01-03","current":8.541308,"twenty":-10.153746,"median":-3.674208,"eighty":15.74151,"marketCap":2844255649},{"date":"2025-01-10","current":8.398747,"twenty":-10.15661,"median":-3.674999,"eighty":15.187166,"marketCap":2796782587},{"date":"2025-01-17","current":8.429738,"twenty":-10.15661,"median":-3.674999,"eighty":14.123802,"marketCap":2807102818},{"date":"2025-01-24","current":8.541308,"twenty":-10.15661,"median":-3.674999,"eighty":12.229294,"marketCap":2844255649},{"date":"2025-01-31","current":8.355358,"twenty":-10.15661,"median":-3.674999,"eighty":11.774076,"marketCap":2782334264},{"date":"2025-02-07","current":8.175606,"twenty":-10.15661,"median":-3.674999,"eighty":11.669683,"marketCap":2722476924},{"date":"2025-02-14","current":7.915276,"twenty":-10.15661,"median":-3.674999,"eighty":11.541332,"marketCap":2635786984},{"date":"2025-02-21","current":12.449378,"twenty":-10.15661,"median":-3.674999,"eighty":11.52593,"marketCap":2639268117},{"date":"2025-02-28","current":11.712888,"twenty":-10.15661,"median":-3.674999,"eighty":11.52593,"marketCap":2483132177},{"date":"2025-03-07","current":11.32214,"twenty":-10.159473,"median":-3.675279,"eighty":11.440344,"marketCap":2400293756},{"date":"2025-03-14","current":10.388159,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2202289726},{"date":"2025-03-21","current":11.045758,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2341700727},{"date":"2025-03-28","current":10.62642,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2252800958},{"date":"2025-04-04","current":9.263569,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":1963876709},{"date":"2025-04-11","current":8.979147,"twenty":-10.15661,"median":-3.674999,"eighty":11.484858,"marketCap":1903579170},{"date":"2025-04-17","current":9.09341,"twenty":-10.15661,"median":-3.674999,"eighty":11.484858,"marketCap":1927802871},{"date":"2025-04-25","current":9.512373,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2016623108},{"date":"2025-05-02","current":9.559983,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2026716317},{"date":"2025-05-09","current":16.384875,"twenty":-10.159473,"median":-3.675279,"eighty":11.531064,"marketCap":2080879082},{"date":"2025-05-16","current":17.045936,"twenty":-10.159473,"median":-3.674208,"eighty":11.65257,"marketCap":2164833858},{"date":"2025-05-23","current":16.148781,"twenty":-10.159473,"median":-3.6534,"eighty":11.72393,"marketCap":2050895233},{"date":"2025-05-30","current":16.510791,"twenty":-10.159473,"median":-3.629041,"eighty":11.766258,"marketCap":2096870468},{"date":"2025-06-06","current":15.771032,"twenty":-10.159473,"median":-3.604398,"eighty":11.937378,"marketCap":2002921076},{"date":"2025-06-13","current":16.447833,"twenty":-10.159473,"median":-3.588007,"eighty":12.388042,"marketCap":2088874775},{"date":"2025-06-20","current":16.038604,"twenty":-10.162337,"median":-3.578159,"eighty":15.511387,"marketCap":2036902771},{"date":"2025-06-27","current":16.55801,"twenty":-10.162337,"median":-3.568226,"eighty":15.739397,"marketCap":2102867237},{"date":"2025-07-03","current":17.061675,"twenty":-10.162337,"median":-3.549185,"eighty":15.841236,"marketCap":2166832781},{"date":"2025-07-11","current":17.848653,"twenty":-10.162337,"median":-3.540618,"eighty":16.000829,"marketCap":2266778942},{"date":"2025-07-18","current":16.998717,"twenty":-10.162337,"median":-3.507581,"eighty":16.081216,"marketCap":2158837088},{"date":"2025-07-25","current":17.518122,"twenty":-10.162337,"median":-3.495637,"eighty":16.142485,"marketCap":2224801554},{"date":"2025-08-01","current":36.742661,"twenty":-10.162337,"median":-3.456698,"eighty":16.1771,"marketCap":2131074349},{"date":"2025-08-08","current":35.570815,"twenty":-10.162337,"median":-3.417502,"eighty":16.307701,"marketCap":2063107278},{"date":"2025-08-15","current":38.224839,"twenty":-10.162337,"median":-3.417502,"eighty":16.351669,"marketCap":2217040670},{"date":"2025-08-22","current":38.500582,"twenty":-10.162337,"median":-3.417502,"eighty":16.434619,"marketCap":2233033750},{"date":"2025-08-29","current":40.534185,"twenty":-10.162337,"median":-3.417502,"eighty":16.560113,"marketCap":2350982712},{"date":"2025-09-05","current":41.740559,"twenty":-10.1652,"median":-3.433,"eighty":16.629128,"marketCap":2420952436},{"date":"2025-09-12","current":41.361413,"twenty":-10.162337,"median":-3.417502,"eighty":16.709109,"marketCap":2398961952},{"date":"2025-09-19","current":41.809495,"twenty":-10.162337,"median":-3.417502,"eighty":16.776195,"marketCap":2424950706},{"date":"2025-09-26","current":38.914196,"twenty":-10.162337,"median":-3.417502,"eighty":16.947295,"marketCap":2257023369},{"date":"2025-10-03","current":38.224839,"twenty":-10.162337,"median":-3.417502,"eighty":17.03964,"marketCap":2217040670},{"date":"2025-10-10","current":37.052932,"twenty":-10.162337,"median":-3.417502,"eighty":17.090583,"marketCap":2149070082},{"date":"2025-10-17","current":37.501014,"twenty":-10.162337,"median":-3.417502,"eighty":17.354431,"marketCap":2175058836},{"date":"2025-10-24","current":38.466114,"twenty":-10.162337,"median":-3.417502,"eighty":17.59682,"marketCap":2231034615},{"date":"2025-10-31","current":-178.753982,"twenty":-10.172486,"median":-3.448497,"eighty":17.810878,"marketCap":2145047787},{"date":"2025-11-07","current":-169.247209,"twenty":-10.219605,"median":-3.476395,"eighty":17.810878,"marketCap":2030966504},{"date":"2025-11-14","current":-174.244666,"twenty":-10.301936,"median":-3.504298,"eighty":17.810878,"marketCap":2090935987},{"date":"2025-11-21","current":-163.916588,"twenty":-10.6072,"median":-3.538772,"eighty":17.810878,"marketCap":1966999055},{"date":"2025-11-28","current":-180.408196,"twenty":-10.799451,"median":-3.540618,"eighty":17.810878,"marketCap":2164898350},{"date":"2025-12-05","current":-174.577829,"twenty":-11.1402,"median":-3.542049,"eighty":17.810878,"marketCap":2094933953},{"date":"2025-12-12","current":-179.90845,"twenty":-11.860354,"median":-3.542049,"eighty":17.810878,"marketCap":2158901402},{"date":"2025-12-19","current":-180.574778,"twenty":-12.666412,"median":-3.542049,"eighty":17.810878,"marketCap":2166897333},{"date":"2025-12-26","current":-181.074523,"twenty":-12.945597,"median":-3.542049,"eighty":17.810878,"marketCap":2172894281},{"date":"2026-01-02","current":-174.244666,"twenty":-13.160355,"median":-3.542049,"eighty":17.810878,"marketCap":2090935987},{"date":"2026-01-09","current":-185.738817,"twenty":-13.430949,"median":-3.542049,"eighty":17.810878,"marketCap":2228865799},{"date":"2026-01-16","current":-191.402601,"twenty":-13.900553,"median":-3.542049,"eighty":17.810878,"marketCap":2296831214},{"date":"2026-01-23","current":-193.06842,"twenty":-36.411218,"median":-3.542049,"eighty":17.810878,"marketCap":2316821042},{"date":"2026-01-30","current":-181.574269,"twenty":-42.996332,"median":-3.544901,"eighty":17.810878,"marketCap":2178891230},{"date":"2026-02-06","current":-186.07198,"twenty":-44.121622,"median":-3.546973,"eighty":17.810878,"marketCap":2232863765},{"date":"2026-02-13","current":-190.236528,"twenty":-45.253331,"median":-3.546973,"eighty":17.810878,"marketCap":2282838334},{"date":"2026-02-20","current":-190.236528,"twenty":-46.332575,"median":-3.546973,"eighty":17.810878,"marketCap":2282838334},{"date":"2026-02-27","current":-8.333483,"twenty":-46.332575,"median":-3.566587,"eighty":17.810878,"marketCap":2358375720},{"date":"2026-03-06","current":-8.041704,"twenty":-46.332575,"median":-3.581442,"eighty":17.810878,"marketCap":2275802360},{"date":"2026-03-13","current":-7.379865,"twenty":-46.332575,"median":-3.589648,"eighty":17.810878,"marketCap":2088501812},{"date":"2026-03-20","current":-7.481341,"twenty":-46.332575,"median":-3.589648,"eighty":17.810878,"marketCap":2117219505},{"date":"2026-03-27","current":-7.623572,"twenty":-46.332575,"median":-3.632324,"eighty":17.810878,"marketCap":2157470827},{"date":"2026-04-02","current":-7.381779,"twenty":-46.332575,"median":-3.670075,"eighty":17.810878,"marketCap":2089043580},{"date":"2026-04-10","current":-7.950703,"twenty":-46.332575,"median":-4.395912,"eighty":17.810878,"marketCap":2250048866},{"date":"2026-04-17","current":-7.950703,"twenty":-46.332575,"median":-4.654495,"eighty":17.810878,"marketCap":2250048866},{"date":"2026-04-24","current":-7.872476,"twenty":-46.332575,"median":-4.7273,"eighty":17.810878,"marketCap":2227910639},{"date":"2026-05-01","current":-10.736806,"twenty":-46.332575,"median":-4.787552,"eighty":17.810878,"marketCap":2308413282},{"date":"2026-05-08","current":-10.480181,"twenty":-46.332575,"median":-4.837762,"eighty":17.810878,"marketCap":2253238933},{"date":"2026-05-15","current":-10.208577,"twenty":-46.332575,"median":-4.837762,"eighty":17.810878,"marketCap":2194844001},{"date":"2026-05-22","current":-10.733054,"twenty":-46.332575,"median":-4.837762,"eighty":17.810878,"marketCap":2307606629},{"date":"2026-05-29","current":-11.398016,"twenty":-46.392533,"median":-4.816423,"eighty":17.848653,"marketCap":2450573531},{"date":"2026-06-05","current":-13.149396,"twenty":-46.332575,"median":-4.837762,"eighty":17.810878,"marketCap":2827120163},{"date":"2026-06-12","current":-13.449097,"twenty":-46.332575,"median":-4.837762,"eighty":17.810878,"marketCap":2891555950},{"date":"2026-06-18","current":-13.580217,"twenty":-46.332575,"median":-4.837762,"eighty":17.810878,"marketCap":2919746607},{"date":"2026-06-26","current":-13.645776,"twenty":-46.392533,"median":-4.816423,"eighty":17.848653,"marketCap":2933841935},{"date":"2026-07-02","current":-13.27115,"twenty":-46.392533,"median":-4.816423,"eighty":17.848653,"marketCap":2853297201},{"date":"2026-07-10","current":-13.243053,"twenty":-46.392533,"median":-5.159038,"eighty":17.848653,"marketCap":2847256346},{"date":"2026-07-17","current":-13.673873,"twenty":-46.392533,"median":-5.361788,"eighty":17.848653,"marketCap":2939882791},{"date":"2026-07-24","current":-13.664508,"twenty":-46.392533,"median":-5.472783,"eighty":17.848653,"marketCap":2937869172},{"date":"2026-07-31","current":-14.104694,"twenty":-46.400028,"median":-5.505341,"eighty":17.858097,"marketCap":3032509235},{"date":"2026-08-07","current":-17.727254,"twenty":-46.400028,"median":-5.52902,"eighty":17.858097,"marketCap":2889542332},{"date":"2026-08-14","current":-18.565123,"twenty":-46.400028,"median":-5.558619,"eighty":17.858097,"marketCap":3026115099},{"date":"2026-08-21","current":-19.540935,"twenty":-46.400028,"median":-5.614856,"eighty":17.858097,"marketCap":3185172380},{"date":"2026-08-28","current":-19.405062,"twenty":-46.400028,"median":-5.644455,"eighty":17.858097,"marketCap":3163025164},{"date":"2026-09-04","current":-18.626884,"twenty":-46.400028,"median":-5.662214,"eighty":17.858097,"marketCap":3036182016},{"date":"2026-09-11","current":-18.923333,"twenty":-46.400028,"median":-5.688853,"eighty":17.858097,"marketCap":3084503215},{"date":"2026-09-18","current":-18.602179,"twenty":-46.400028,"median":-5.718451,"eighty":17.858097,"marketCap":3032155249},{"date":"2026-09-25","current":-18.78746,"twenty":-46.400028,"median":-5.721411,"eighty":17.858097,"marketCap":3062355999},{"date":"2026-10-02","current":-19.046853,"twenty":-46.400028,"median":-5.721411,"eighty":17.858097,"marketCap":3104637048}],"updateTime":1791064447158},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PK\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2637312907","title":"Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2637312907","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637312907?lang=en_us&edition=fundamental","pubTime":"2026-05-22 21:15","pubTimestamp":1779455700,"startTime":"0","endTime":"0","summary":"PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemiaMitapivat is now approved for thalassemia in the U.S., Sa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/22/3300143/31990/en/Agios-PYRUKYND-mitapivat-Approved-in-the-European-Union-for-Adults-with-Thalassemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLDYK493.USD","IE00B64QTZ34.USD","BK4161","BK4218","BK4181","EPV","IE00BD6J9T35.USD","RBC","BK4201","PK","BK4156","EC","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357561","title":"Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357561","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357561?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:01","pubTimestamp":1779397260,"startTime":"0","endTime":"0","summary":"– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant – – Data underscoring un","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299789/0/en/Syndax-Announces-Four-Revuforj-revumenib-Abstracts-Accepted-for-ASCO-2026-Including-an-Oral-Presentation-of-Post-Transplant-Data.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","BK4218","PK","LU1699723380.USD","LU0566484027.USD","BK4212","ECG","LU2355687059.USD","BK4533","HSCT","LU1571399168.USD","BK4129","POST","BK4588","BK4107","LU0985320562.USD","LU1559883803.SGD","ALL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636859472","title":"Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2636859472","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636859472?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:45","pubTimestamp":1779194700,"startTime":"0","endTime":"0","summary":"HIGHLIGHTS New Phase 2b study builds on compelling Phase 1b/2a ACCENT study data to lay foundation for Phase 3 registrational studyFocus on investigating new, daily dosing of narmafotinib in combinati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/19/3297510/0/en/Amplia-Therapeutics-Launches-First-Stage-of-Registration-Enabling-Trial-of-Narmafotinib.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","BK4139","BK4007","BK4181","LENZ","BK4539","SSI","INNMF","PK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635082143","title":"Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635082143","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635082143?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:45","pubTimestamp":1778849100,"startTime":"0","endTime":"0","summary":"Entering a Transformative Stage by Advancing PRP to a Pivotal, Phase 1b, FIH, Clinical Study Whilst Undertaking Additional Research into Age-Related Chronic DiseasesMELBOURNE, Australia, May  15, 2026","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/15/3295851/0/en/Propanc-Biopharma-Provides-Corporate-Update-and-Reports-Third-Quarter-2025-26-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","BK4181","BK4218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635725331","title":"Press Release: Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635725331","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635725331?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:15","pubTimestamp":1778789700,"startTime":"0","endTime":"0","summary":"ZUNVEYL generated net product revenue of $3.5 million in Q1 2026, a 40% quarter-over-quarter increase. Cumulative net product revenue totaled $10.3 million through first four full quarters of launch. Q1 2026 bottles dispensed increased 23% quarter-over-quarter to 6,054, with March representing the strongest month of demand since launch. Approximately 75% of prescribers and 81% of facilities demonstrated repeat utilization, reinforcing durable adoption trends. Real-world clinical studies active, with BEACON enrolling ahead of schedule. Cash and cash equivalents totaled $54 million as of March 31, 2026, supporting the Company's continued target of operating profitability in 2027. Company to host conference call and webcast today, May 14, at 4:30 p.m. ET. Alpha Cognition Inc.  , a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACOG","PK","BK4139","BK4181","BK4218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635712585","title":"Galmed reports results from first-in-man PK study of Aramchol Meglumine","url":"https://stock-news.laohu8.com/highlight/detail?id=2635712585","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635712585?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:53","pubTimestamp":1778759584,"startTime":"0","endTime":"0","summary":"Galmed (GLMD) announced milestone results from a Phase 1 PK study in healthy subjects. The overall objective of the study was to identify the dose ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/galmed-reports-results-from-first-in-man-pk-study-of-aramchol-meglumine-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/galmed-reports-results-from-first-in-man-pk-study-of-aramchol-meglumine-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLMD","PK","BK4139","BK4218","BK4181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635941758","title":"Press Release: Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635941758","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635941758?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:03","pubTimestamp":1778702580,"startTime":"0","endTime":"0","summary":"ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026. ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected 2027. Post-offering cash, cash equivalents and marketable securities expected to fund Company through BLA for ORKA-001. MENLO PARK, Calif., May 13, 2026  -- Oruka Therapeutics, Inc.  , a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis , today reported first quarter 2026 financial results and provided a corporate update.\"This was an important period for our company as we saw interim data for ORKA-001 that hit the upper end of our expectations on all aspects,\" said Lawrence Klein, PhD, Chief Executive Officer of Oruka. \"Based on this data we were able to strengthen our balance sheet and provide runway through completion of late-stage development for that pr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","03160","BK4539","PD","BK4023","BK4604","BK4588","PK","ORKA","BK4099","BK4007","LENZ","LU1169589451.USD","BK4585","BK4218","TM","BK4139","LU1169590202.USD","BK4555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635378032","title":"Park Hotels & Resorts Price Target Maintained With a $12.00/Share by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2635378032","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635378032?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:17","pubTimestamp":1778678220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PK/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2026 09:17 ET (13:17 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","BK4181","BK4218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635240589","title":"Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635240589","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635240589?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616300,"startTime":"0","endTime":"0","summary":"C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of HC","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3293389/0/en/Atea-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","SOF","PK","BK4007","AVIR","BK4181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635249185","title":"Park Hotels & Resorts Is Maintained at Equal-Weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2635249185","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635249185?lang=en_us&edition=fundamental","pubTime":"2026-05-13 01:15","pubTimestamp":1778606100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PK/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 13:15 ET (17:15 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","BK4218","PK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634217337","title":"Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2634217337","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634217337?lang=en_us&edition=fundamental","pubTime":"2026-05-12 21:31","pubTimestamp":1778592660,"startTime":"0","endTime":"0","summary":"sNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval pathway Confirmatory trial designed to demonstrate clinical benefit of mitapivat on reducing","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3293011/31990/en/Agios-Submits-sNDA-to-FDA-for-U-S-Accelerated-Approval-of-Mitapivat-in-Sickle-Cell-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","PK","BK4585","BK4181","LABU","BK4218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634721329","title":"Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2634721329","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634721329?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:00","pubTimestamp":1778583600,"startTime":"0","endTime":"0","summary":"Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteersOV329 showed favorable safety","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3292680/0/en/Ovid-Therapeutics-Reports-Business-Updates-and-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0256331488.USD","PK","BK4007","BK4139","BK4539","BK4588","APA","BK4181","BK4213","BK4585","LENZ","BK4218","IS","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634218216","title":"Press Release: Sionna Therapeutics Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2634218216","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634218216?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:00","pubTimestamp":1778583600,"startTime":"0","endTime":"0","summary":"Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of 2026. Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is also on track for topline data in the summer of 2026. Maintained strong cash position with approximately $289.9 million in cash and cash equivalents, expected to fund operations into 2028. \"We entered 2026 with strong execution across our programs, highlighted by the recent completion of enrollment in our proof-of-concept Phase 2a trial of SION-719, an important milestone for Sionna,\" said Mike Cloonan, President and Chief Executive Officer of Sionna. \"With both of our clinical stage NBD1 stabilizer programs on track for topline readouts this summer, we remain focused on advancing these first-in-class product candidat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4093","SION","SOC","PK","BK4218","CF","BK4585","BK4213","BK4181","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232653","title":"Erasca Reports First Quarter 2026 Business Updates and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232653","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232653?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:01","pubTimestamp":1778529660,"startTime":"0","endTime":"0","summary":"Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3292285/0/en/Erasca-Reports-First-Quarter-2026-Business-Updates-and-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","BK4187","BK4139","BK4218","IE00B66KJ199.SGD","IE00B7SZL793.SGD","PK","DCO","BK4181","IE00B19Z4B17.USD","BK4539","LU1559883803.SGD","IE0031619046.USD","ERAS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634928323","title":"MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2634928323","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634928323?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:00","pubTimestamp":1778497200,"startTime":"0","endTime":"0","summary":"Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo) MBX 4291 generally well tolerated","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3291731/0/en/MBX-Biosciences-Provides-Obesity-Portfolio-Update-Including-Initial-Phase-1-Data-for-MBX-4291-Supporting-Potential-for-Once-Monthly-Dosing.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBH","BK4588","IE00BFXG0V08.USD","LU2413666426.HKD","LU1721428933.USD","LU2413666699.HKD","MTD","LU1093756325.SGD","LU2211817866.USD","BK4218","BK4585","BK4181","LU0347712357.USD","MBX","BK4533","BK4007","IE00BYQQ9H92.USD","BK4121","BK4567","LU1093756168.USD","BK4548","PK","IE00B5TLWC47.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634828842","title":"Press Release: Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2634828842","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634828842?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:00","pubTimestamp":1778497200,"startTime":"0","endTime":"0","summary":"-- Elraglusib oral tablet formulation to drive next-phase clinical. -- FDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer. patients, with focus on metastatic melanoma, NSCLC, colorectal, and. pancreatic cancers with initiation planned for 2H 2026. To support this initiative, the Company recently received Investigational New Drug  clearance from FDA to conduct a Phase 1/2 study designed to demonstrate that a higher overall exposure to elraglusib can be achieved with the oral formulation compared to the IV formulation. The study will evaluate the safety and potential efficacy of the oral formulation as a monotherapy in solid tumor patients, including those with metastatic melanoma, NSCLC, colorectal, and pancreatic cancers, based on evidence of efficacy of the IV formulation in prior clinical studies and machine learning therapeutic target analyses.\"Advancing the elraglusib oral tablet is an important element to the success of our overall development strategy,\" sai","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0347712357.USD","LU1093756168.USD","LU2413666426.HKD","BK4181","BK4081","ACTU","LU1093756325.SGD","BK4567","IE00BYQQ9H92.USD","BK4585","EMA","BK4533","BK4588","PK","BK4218","BK4139","BK4121","LU2413666699.HKD","LU2211817866.USD","IND","LABU","BK4548","IE00BFXG0V08.USD","LU1721428933.USD","IE00B5TLWC47.USD","MTD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179294583","title":"Live Broadcast Preview: Guangdong BA League - Meizhou vs. Qingyuan! Tonight, Witness the \"Qing-Mei\" Rivalry Face-Off","url":"https://stock-news.laohu8.com/highlight/detail?id=1179294583","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179294583?lang=en_us&edition=fundamental","pubTime":"2026-05-10 17:10","pubTimestamp":1778404256,"startTime":"0","endTime":"0","summary":"People often speak of the gentle, enduring bond of \"childhood sweethearts,\" but this time, we set aside sentimentality for pure competition. In the seventh round of the Guangdong BA regular season,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","PK","BK4218","LU1435385759.SGD","BK4585","BK4588","BK4564","BK4551","BOEG","LU1429558221.USD","BA","BOEU","BK4181","BK4085","LU2326559502.SGD","BOED","BK4187","IE000M9KFDE8.USD","VS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633172937","title":"Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633172937","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633172937?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:05","pubTimestamp":1778184300,"startTime":"0","endTime":"0","summary":"Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201 HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling from H","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290557/0/en/Absci-Reports-Business-Updates-and-First-Quarter-2026-Financial-and-Operating-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4587","AI","BK4543","PK","BK4585","AIPO","BK4023","BK4528","ARTY","BK4181","BK4551","CHAT","SID","AGIX","BK4006","BK4218","AIYY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633814551","title":"Press Release: Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633814551","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633814551?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Phase 2a follow-up period data for RAP-219 in focal onset seizures  demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12. RAP-219 Phase 2 trial in bipolar mania topline results now expected in the fourth quarter of 2026, ahead of previous 1H 2027 guidance. Pipeline programs, including RAP-219 long-acting injectable formulation, RAP-219 in primary generalized tonic-clonic seizures, and <ALPHA>6<BETA>4 nAChR in chronic pain and migraine, continue to advance. Strategic collaboration and license agreement entered into with Tenacia Biotechnology to develop and commercialize RAP-219 in Greater China across indications. \"We entered 2026 with strong momentum across the RAP-219 development program, highlighted by compelling new follow-up Phase 2a data recently presented at AAN that further reinforces RAP-219's treatment effect in focal onset seizures and builds confidence as we enter our Phase 3 trials,\" said Abraham N. Cees","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","RAPP","BK4181","PK","BK4007","AAN","BK4178"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633453731","title":"Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633453731","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633453731?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at ER","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289829/0/en/Climb-Bio-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4181","LU1169590202.USD","BK4218","BK4023","BK4077","PK","PD","BK4199","ITP","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":6,"totalSize":155,"code":"91000000","status":"200"}]}}